Risankizumab (by Subcutaneous Injection) for Moderate to Severe Chronic Plaque Psoriasis

featured image
Indications: Plaque psoriasis
Therapeutic Areas: Dermatology
Year: 2017

Risankizumab is a drug which is injected into the skin. It works in a unique way by blocking a specific process which allows the body’s immune cells (specifically T-cells) from attacking and damaging the skin. Risankizumab is currently being trialled in a range of diseases involving the immune system including Crohn’s disease, and psoriatic arthritis.